PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för tesamorelin. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

31 hits

Bibliografisk träff 2020-08-20

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.

Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK.

JCI Insight · research support, n.i.h., intramural; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1172/jci.insight.140134

Bibliografisk träff 2019-10-11

Tesamorelin, liver fat, and NAFLD in the setting of HIV.

Audsley J, Sasadeusz J, Lewin SR.

Lancet HIV · comment; journal article · DOI 10.1016/s2352-3018(19)30331-5

Bibliografisk träff 2019-10-11

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK.

Lancet HIV · research support, n.i.h., intramural; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1016/s2352-3018(19)30338-8

Bibliografisk träff 2019-01-01

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.

Adrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM.

J Frailty Aging · research-article; randomized controlled trial; journal article · DOI 10.14283/jfa.2018.45

Bibliografisk träff 2017-10-01

Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK.

AIDS · research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/qad.0000000000001614

Bibliografisk träff 2017-06-15

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial.

Clemmons DR, Miller S, Mamputu JC.

PLoS One · research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1371/journal.pone.0179538

Bibliografisk träff 2015-10-12

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1371/journal.pone.0140358

Bibliografisk träff 2015-04-21

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M.

J Pharmacokinet Pharmacodyn · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10928-015-9416-2

Bibliografisk träff 2015-03-01

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

González-Sales M, Barrière O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M.

Clin Pharmacokinet · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40262-014-0202-x

Bibliografisk träff 2014-07-01

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.

JAMA · research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1001/jama.2014.8334

Bibliografisk träff 2013-12-20

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK.

J Clin Endocrinol Metab · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1210/jc.2013-3436

Bibliografisk träff 2013-05-15

Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy Volunteers.

Teng S, Potvin D, Mamputu JC, Vincent G, Zoltowska M, Morin J, Hatimi S, Michaud SE, High K, Ducharme MP.

Clin Pharmacol Drug Dev · journal article · DOI 10.1002/cpdd.27

Bibliografisk träff 2012-08-28

Neuroendocrinology: Tesamorelin can improve cognitive function.

McLarnon A.

Nat Rev Endocrinol · journal article · DOI 10.1038/nrendo.2012.151

Bibliografisk träff 2012-04-10

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/cis251

Bibliografisk träff 2012-01-31

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Spooner LM, Olin JL.

Ann Pharmacother · review; journal article · DOI 10.1345/aph.1q629

Bibliografisk träff 2011-12-01

Spotlight on tesamorelin in HIV-associated lipodystrophy.

Dhillon S.

BioDrugs · review; journal article · DOI 10.2165/11208290-000000000-00000

Bibliografisk träff 2011-07-10

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy.

Bedimo R.

HIV AIDS (Auckl) · review-article; journal article · DOI 10.2147/hiv.s14561

Bibliografisk träff 2011-06-01

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS · clinical trial, phase iii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1097/qad.0b013e328347f3f1

Bibliografisk träff 2011-06-01

Tesamorelin: a novel therapeutic option for HIV/HAART-associated increased visceral adipose tissue.

Falutz J.

Drugs Today (Barc) · journal article · DOI 10.1358/dot.2011.47.6.1603439

Bibliografisk träff 2011-05-01

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Dhillon S.

Drugs · review; journal article · DOI 10.2165/11202240-000000000-00000

Bibliografisk träff 2011-04-01

Tesamorelin: A hope for ART-induced lipodystrophy.

Patel A, Gandhi H, Upaganlawar A.

J Pharm Bioallied Sci · letter; journal article · DOI 10.4103/0975-7406.80763

Bibliografisk träff 2011-02-01

Tesamorelin.

Grunfeld C, Dritselis A, Kirkpatrick P.

Nat Rev Drug Discov · news · DOI 10.1038/nrd3362

Bibliografisk träff 2011-01-01

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy.

Mateo MG, Gutiérrez MDM, Domingo P.

Expert Rev Endocrinol Metab · journal article · DOI 10.1586/eem.10.83

Bibliografisk träff 2010-12-01

FDA approves tesamorelin for HIV-related lipodystrophy.

Traynor K.

Am J Health Syst Pharm · news · DOI 10.2146/news100082

Bibliografisk träff 2010-10-13

Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.

Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK.

J Clin Endocrinol Metab · research-article; journal article; research support, n.i.h., extramural · DOI 10.1210/jc.2010-1587

Bibliografisk träff 2010-06-16

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab · research support, non-u.s. gov't; journal article · DOI 10.1210/jc.2010-0490

Bibliografisk träff 2010-06-01

Tesamorelin update.

O'Neal R.

BETA · newspaper article; journal article

Bibliografisk träff 2010-03-01

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr · randomized controlled trial; journal article · DOI 10.1097/qai.0b013e3181cbdaff

Bibliografisk träff 2009-03-01

Tesamorelin, a human growth hormone releasing factor analogue.

Wang Y, Tomlinson B.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543780802707658

Bibliografisk träff 2007-01-01

TH9507: an experimental treatment for lipodystrophy.

Monroe A.

BETA · newspaper article; journal article